ReviewBMC pediatrics2026
Late-onset cobalamin C defect with a rare MMACHC c.457 C > T variant: a case report and literature review.
Review in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCobalamin C (cblC) defect, also referred to as combined methylmalonic acidemia and homocystinuria, is the most common inborn error of intracellular cobalamin metabolism. Late-onset cblC defect often presents with atypical and heterogeneous manifestations, particularly neuropsychiatric symptoms, which may lead to misdiagnosis and delayed treatment. CASE PRESENTATION: We report a 13-year-old girl with late-onset cblC defect who presented with progressive cognitive impairment, psychiatric and behavioral abnormalities, and motor dysfunction. Because of these atypical manifestations, she was initially misdiagnosed with autoimmune encephalitis. Laboratory evaluation showed markedly elevated plasma total homocysteine, decreased methionine, mildly increased propionylcarnitine with elevated C3/C2 and C3/C0 ratios, and markedly increased urinary methylmalonic acid and methylcitrate. Genetic testing identified compound heterozygous pathogenic variants in the MMACHC gene: c.482G > A (p.Arg161Gln, maternally inherited) and c.457 C > T (p.Arg153Ter), the latter being rarely reported in China. Following treatment with hydroxocobalamin, folate, betaine, and L-carnitine, the patient showed marked biochemical improvement and partial clinical recovery, although residual cognitive impairment and gait disturbance persisted.
conclusionsThis case expands the genotypic spectrum of cblC defect in China and highlights the importance of metabolic screening and genetic testing in children and adolescents with otherwise unexplained neuropsychiatric manifestations. Early recognition and targeted treatment are crucial for improving long-term neurological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.